Rheumatology · Medical Literature
The Efficacy and Safety of Pregabalin Combined with Venlafaxine in Fibromyalgia Patients: Protocol for a Prospective, Randomized, Open-Label, Blinded-Endpoint Trial.
Abstract
Fibromyalgia (FM) is a chronic condition characterized by widespread pain and a range of somatic and psychological symptoms that impose a substantial burden on patients. While pregabalin is an approved and effective monotherapy for many individuals with FM, the efficacy of this medication is often incomplete, particularly for symptoms like fatigue and anxiety. Combination therapy incorporating selective serotonin and norepinephrine reuptake inhibitors (SNRIs), such as duloxetine, has shown promise for enhancing therapeutic outcomes. Venlafaxine, an SNRI with demonstrated efficacy as an FM treatment, has a distinct pharmacological mechanism from pregabalin. However, the synergistic potential of pregabalin and venlafaxine in combination has not been formally evaluated. This study protocol describes a trial designed to test the hypothesis that the combination of pregabalin and venlafaxine is superior to pregabalin monotherapy in providing pain relief to patients with FM. This is a multicenter, prospective, randomized, open-label, blinded-endpoint study. This study will be conducted at 7 different hospitals. We will recruit 750 adults with a diagnosis of FM and moderate-to-severe pain. Patients will be randomly assigned in a one-to-one ratio to receive either pregabalin monotherapy or combination therapy consisting of pregabalin and venlafaxine for 12 weeks. Both groups will follow a flexible, forced-titration schedule to achieve the maximum tolerated dose. While the patients and treating physicians will be aware of the treatment allocation, the outcome assessors will remain blinded. The primary outcome is the mean daily pain intensity at week 4, measured on an 11-point numeric rating scale. Secondary outcomes will be evaluated at baseline and at weeks one, 2, 4, 8, and 12 after the treatment initiation. Secondary outcomes include the worst pain intensity, the responder rates (≥ 30% and ≥ 50% pain reduction), the dose of pregabalin and/or venlafaxine, the Revised FM Impact Questionnaire, the Brief Pain Inventory severity and interference subscales, the 36-Item Short Form Survey (SF-36), the Medical Outcomes Study Sleep Scale, the Beck Depression Inventory-II, and adverse events (AEs) occuring throughout the study. Statistical analyses will be performed on the modified intention-to-treat population. An open-label design will be employed, with patient follow-up limited to 12 weeks. If the combination of pregabalin and venlafaxine proves to be more effective and better tolerated than pregabalin monotherapy, the combination therapy could establish a new standard of care for FM patients who struggle to achieve sufficient pain relief through nonpharmacological therapies.
Clinical relevance
In adults with fibromyalgia and moderate-to-severe pain, is the combination of pregabalin plus venlafaxine superior to pregabalin monotherapy in reducing pain and improving overall symptom burden? __SNAPSHOT__ {"studyDesign":"Protocol for a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial","setting":"7 hospitals; country not specified in the abstract (multicenter)","sampleSize":"Planned n=750 adults with fibromyalgia and moderate-to-severe pain; allocation details not reported in the abstract","population":"Adults meeting a formal diagnosis of fibromyalgia with moderate-to-severe pain; additional inclusion/exclusion criteria not detailed in the abstract","intervention":"Pregabalin combined with venlafaxine (an SNRI)","comparator":"Pregabalin monotherapy","primaryOutcome":"Pain relief; specific metric (e.g., NRS/VAS threshold, percentage reduction, responder rate) not detailed in the abstract","followUp":"Not reported in the abstract","fundingSource":"Not reported"}
Key findings
This publication is a trial protocol, not a results paper. No outcome data, effect sizes, p-values, confidence intervals, or adverse event frequencies are reported. The central hypothesis — that pregabalin plus venlafaxine provides superior pain relief compared with pregabalin monotherapy — remains untested at the time of this publication. No NNT, NNH, absolute risk differences, or relative risk estimates can be calculated or presented. The rationale for the combination is mechanistic: pregabalin acts via α2δ calcium channel blockade to reduce excitatory neurotransmitter release, while venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), augments descending inhibitory pain pathways — mechanisms that are pharmacologically distinct and theoretically complementary. Supportive precedent exists from a prior randomized trial of pregabalin combined with duloxetine (another SNRI), which demonstrated superiority of combination therapy over each monotherapy across pain, functional, and quality-of-life domains, though that trial was small (n=41 completers) and used a crossover design.
Practice implications
This paper establishes only the design and rationale for a planned trial; it does not establish efficacy, safety, or clinical superiority of pregabalin plus venlafaxine over pregabalin alone. No practice inference can be drawn from this protocol. The investigational question is clinically important: current FDA-approved monotherapies for fibromyalgia — pregabalin, duloxetine, and milnacipran — provide meaningful pain relief in only a minority of patients, with systematic reviews estimating approximately 30% pain reduction in roughly 30% of treated individuals, while adverse effects and poor adherence further limit their real-world utility. The pharmacological rationale for combining an α2δ ligand with an SNRI is biologically plausible, and analog evidence from pregabalin-duloxetine combination trials is hypothesis-generating. However, venlafaxine has not been formally studied in combination with pregabalin in fibromyalgia, and the magnitude and clinical significance of any additive or synergistic effect — as well as the additive adverse effect burden — remain entirely unknown pending trial completion. Results, when available, will need to be evaluated for both statistical significance and minimal clinically important difference thresholds on the primary pain outcome. Generalizability may be limited depending on the enrolled population's demographic and comorbidity profile, which is not detailed in the abstract. Only the abstract was available for this review. __LIMITATIONS__ 1. This is a protocol paper only; no results are available, precluding any assessment of efficacy, safety, or effect size. 2. Open-label design (participants and treating clinicians are unblinded) introduces performance and expectation bias, potentially inflating perceived benefit; endpoint blinding (PROBE design) partially mitigates ascertainment bias for adjudicated outcomes. 3. The primary outcome metric and its minimally clinically important difference threshold are not specified in the abstract. 4. Follow-up duration is not reported in the abstract, raising questions about long-term durability of any observed effect. 5. Sample size of 750 may be adequate for a primary pain endpoint but potentially underpowered for less common adverse events or subgroup analyses. 6. The multicenter design across 7 sites introduces potential heterogeneity in clinical practice and patient selection. 7. Venlafaxine is not FDA-approved for fibromyalgia, and its comparative efficacy versus duloxetine in this condition is not established, limiting direct extrapolation. 8. Funding source is not disclosed, making it impossible to assess potential conflicts of interest. 9. Patient characteristics, comorbidity burden, concomitant medications, and diagnostic criteria used are not detailed in the abstract. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ This is a trial protocol — no efficacy or safety data are yet available. The study addresses a clinically important and mechanistically plausible question about whether adding venlafaxine to pregabalin improves fibromyalgia outcomes beyond pregabalin monotherapy. Clinicians should not alter prescribing practice based on this publication; the completed trial results will be needed to evaluate whether the combination offers a clinically meaningful benefit-to-risk advantage.